Tasaduq H Wani

Dr. Tasaduq H Wani

University of North Carolina at Charlotte, Charlotte, Michigan, USA
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2017 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
TWTasaduq H Wani
Tasaduq H Wani
ACAnindita Chakrabarty
Anindita Chakrabarty
Norio ShibataNorio Shibata
Norio Shibata
HYHiroshi Yamazaki
Hiroshi Yamazaki
FGFrederick Peter Guengerich
Frederick Peter Guengerich
GCGoutam Chowdhury
Goutam Chowdhury

22 December 2017 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
UKUdeshika Lakmini Kariyawasam
Udeshika Lakmini Kariyawasam
ASAngamuthu Selvapandiyan
Angamuthu Selvapandiyan
KRKeshav Rai
Keshav Rai
TWTasaduq H Wani
Tasaduq H Wani
KVKavita Vats
Kavita Vats
NKNadira Karunaweera
Nadira Karunaweera
Leishmania donovani is the etiological agent of visceral leishmaniasis (VL) in the Indian subcontinent. However, it is also known to cause cutaneous leishmaniasis (CL) in Sri Lanka. Sri Lankan L. donovani differs from other L. donovani strains, both at the molecular and biochemical level. To investigate the different species or strain-specific differences of L. donovani in Sri Lanka we evaluated sequence variation of the kinetoplastid DNA (kDNA). Parasites isolated from skin lesions of 34 CL patients and bone marrow aspirates from 4 VL patients were genotyped using the kDNA minicircle PCR analysis. A total of 301 minicircle sequences that included sequences from Sri Lanka, India, Nepal and six reference species of Leishmania were analyzed. Haplotype diversity of Sri Lankan isolates were high (H d = 0.757) with strong inter-geographical genetic differentiation (F ST > 0.25). In this study, L. donovani isolates clustered according to their geographic origin, while Sri Lankan isolates formed a separate cluster and were clearly distinct from other Leishmania species. Within the Sri Lankan group, there were three distinct sub-clusters formed, from CL patients who responded to standard antimony therapy, CL patients who responded poorly to antimony therapy and from VL patients. There was no specific clustering of sequences based on geographical origin within Sri Lanka. This study reveals high levels of haplotype diversity of L. donovani in Sri Lanka with a distinct genetic association with clinically relevant phenotypic characteristics. The use of genetic tools to identify clinically relevant features of Leishmania parasites has important therapeutic implications for leishmaniasis.

13 June 2018 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
TWTasaduq H Wani
Tasaduq H Wani
SSSreeraj Surendran
Sreeraj Surendran
AJAnal Jana
Anal Jana
ACAnindita Chakrabarty
Anindita Chakrabarty
GCGoutam Chowdhury
Goutam Chowdhury

11 September 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
TWTasaduq H Wani
Tasaduq H Wani
SSSreeraj Surendran
Sreeraj Surendran
VMVishnu S. Mishra
Vishnu S. Mishra
JCJaya Chaturvedi
Jaya Chaturvedi
GCGoutam Chowdhury
Goutam Chowdhury
ACAnindita Chakrabarty
Anindita Chakrabarty
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Tasaduq H. Wani1, *, Sreeraj Surendran1, *, Vishnu S. Mishra1, Jaya Chaturvedi1, Goutam Chowdhury2 and Anindita Chakrabarty1 1Department of Life Sciences, Shiv Nadar University, Greater Noida, UP 201314, India 2Department of Chemistry, Shiv Nadar University, Greater Noida, UP 201314, India *These authors contributed equally and should be considered as joint first authors Correspondence to: Anindita Chakrabarty, email: anindita.chakrabarty@snu.edu.in Keywords: breast cancer; survivin; YM155; drug-adaptation; DNA damage Abbreviations: BC: breast cancer; YMR: YM155-resistant; P: parental Received: April 26, 2018 Accepted: August 23, 2018 Published: September 11, 2018 ABSTRACT Sepantronium bromide (YM155), originally developed against the anti-apoptotic protein survivin, performed exceptionally well in pre-clinical and phase I clinical trials. However, in phase II trials of several cancer types including breast cancer it performed poorly. Additionally, no definitive correlation between survivin level and response to therapy was found. In an attempt to understand the true reason of the late-stage failure of this promising drug, we developed YM155-resistant MCF-7 breast cancer cell line and characterized side-by-side with the drug-naïve parental cell line. Chronic YM155 treatment resulted in downregulation of survivin expression yet triggered cellular responses typical of adaptation to persistent DNA damage. Lowering endogenous antioxidant glutathione level and activity of cell cycle check-point kinase restored YM155 activity. Thus, contrary to its development as a survivin suppressant, YM155 primarily acts as a chemotherapeutic drug causing oxidative stress-mediated DNA damage. Adaptation to long-term exposure to YM155 can be prevented and/or overcome by interfering with detoxification and DNA damage-response pathways. Finally, proteins associated with DNA damage-response pathway will be more appropriate as predictive biomarkers of YM155 in breast tumor cells.

18 June 2019 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
ACAnindita Chakrabarty
Anindita Chakrabarty
SSSreeraj Surendran
Sreeraj Surendran
NBNeil E Bhola
Neil E Bhola
VMVishnu S Mishra
Vishnu S Mishra
TWTasaduq H Wani
Tasaduq H Wani
GCGoutam Chowdhury
Goutam Chowdhury
In pre-clinical models, co-existence of Human Epidermal Growth Factor Receptor-2 (HER2)-amplification and PI3K catalytic subunit (PIK3CA) mutations results in aggressive, anti-HER2 therapy-resistant breast tumors. This is not always reflected in clinical setting. We speculated that the complex interaction between the HER2 and PIK3CA oncogenes is responsible for such inconsistency. We performed series of biochemical, molecular and cellular assays on genetically engineered isogenic mammary epithelial cell lines and breast cancer cells expressing both oncogenes. In vitro observations were validated in xenografts models. We showed that H1047R, one of the most common PIK3CA mutations, is responsible for endowing a senescence-like state in mammary epithelial cells overexpressing HER2. Instead of imposing a permanent growth arrest characteristic of oncogene-induced senescence, the proteome secreted by the mutant cells promotes stem cell enrichment, angiogenesis, epithelial-to-mesenchymal transition, altered immune surveillance and acute vulnerability toward HSP90 inhibition. We inferred that the pleiotropism, as observed here, conferred by the mutated oncogene, depending on the host microenvironment, contributes to conflicting pre-clinical and clinical characteristics of HER2+, mutated PIK3CA-bearing tumor cells. We also came up with a plausible model for evolution of breast tumors from mammary epithelial cells harboring these two molecular lesions.

21 June 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
SOSiddhi Omkar
Siddhi Omkar
TWTasaduq H Wani
Tasaduq H Wani
BZBo Zheng
Bo Zheng
MMMegan M Mitchem
Megan M Mitchem
ATAndrew Truman
Andrew Truman
Molecular chaperones such as Hsp70 and Hsp90 help fold and activate proteins in important signal transduction pathways that include DNA damage response (DDR). Previous studies have suggested that the levels of the mammalian APE2 exonuclease, a protein critical for DNA repair, may be dependent on chaperone activity. In this study, we demonstrate that the budding yeast Apn2 exonuclease interacts with molecular chaperones Ssa1 and Hsp82 and the co-chaperone Ydj1. Although Apn2 does not display a binding preference for any specific cytosolic Hsp70 or Hsp90 paralog, Ssa1 is unable to support Apn2 stability when present as the sole Ssa in the cell. Demonstrating conservation of this mechanism, the exonuclease APE2 also binds to Hsp70 and Hsp90 in mammalian cells. Inhibition of chaperone function via specific small molecule inhibitors results in a rapid loss of APE2 in a range of cancer cell lines. Taken together, these data identify APE2 and Apn2 as clients of the chaperone system in yeast and mammalian cells and suggest that chaperone inhibition may form the basis of novel anticancer therapies that target APE2-mediated processes.